Boost to Biocon's biosimilar business as Bengaluru units get European nod

Facilities were inspected by the European Medicines Agency in March; Analysts foresee firm posting double-digit growth in revenue and profits despite rising competition

Biocon has received the European drug regulatory agency's approval for its facilities in Bengaluru, enabling it to continue and enhance its biosimilar production for the Continent's markets.

The company said on Friday that it has received the Certificate of GMP (Good Manufacturing Practice) compliance from European Medicines Agency (EMA) for its Biologics Drug Product (DP) and Drug Substance (DS) facilities at Biocon Park, Bengaluru. The facilities, which manufacture Biocon’s portfolio of biosimilars, were inspected by